New drug 611 shows promise for kids with severe eczema
NCT ID NCT06324812
First seen Jun 24, 2026 · Last updated Jul 02, 2026 · Updated 3 times
Summary
This study tests a new antibody drug called 611 in 124 Chinese children and adolescents aged 6 to 18 with moderate to severe atopic dermatitis (eczema). The drug targets a protein involved in inflammation. The main goals are to check safety and how the drug moves through the body, while also looking at whether it improves eczema symptoms. Participants receive injections every 2 or 4 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Anti-interleukin-4 receptor alpha monoclonal antibody (611)
- What this could lead to
- If successful, this could provide a new treatment option for children and teens with moderate to severe eczema that is not well controlled by current therapies.
- What could go wrong
- This is an early-phase trial (phase 1/2) with a small number of participants, so safety and effectiveness are not yet proven. The drug may cause side effects or not work as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS ATOPIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Children's Hospital
Beijing, Beijing Municipality, 100003, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Real-World dupixent: does it live up to the hype for eczema?
- Scientists hunt for biological clues to severe childhood eczema
- Can a drug calm severe eczema itch when the rash is mild? a new study investigates
- Eczema drug nemolizumab put to the vaccine test
- New eczema drug enters first human tests
- Eczema drug study pulled before it started